nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—ALB—Fluorouracil—urinary bladder cancer	0.0414	0.393	CbGbCtD
Gliclazide—ABCC8—penis—urinary bladder cancer	0.0349	0.249	CbGeAlD
Gliclazide—ALB—Methotrexate—urinary bladder cancer	0.0229	0.216	CbGbCtD
Gliclazide—CYP2C9—Fluorouracil—urinary bladder cancer	0.0223	0.212	CbGbCtD
Gliclazide—CYP2C9—Cisplatin—urinary bladder cancer	0.019	0.18	CbGbCtD
Gliclazide—CYP2C19—urine—urinary bladder cancer	0.0134	0.0955	CbGeAlD
Gliclazide—VEGFA—prostate gland—urinary bladder cancer	0.0126	0.0903	CbGeAlD
Gliclazide—CYP2C9—urine—urinary bladder cancer	0.0104	0.0741	CbGeAlD
Gliclazide—VEGFA—smooth muscle tissue—urinary bladder cancer	0.00895	0.0639	CbGeAlD
Gliclazide—VEGFA—urethra—urinary bladder cancer	0.00846	0.0604	CbGeAlD
Gliclazide—ABCC8—prostate gland—urinary bladder cancer	0.00833	0.0595	CbGeAlD
Gliclazide—ABCC8—seminal vesicle—urinary bladder cancer	0.00704	0.0503	CbGeAlD
Gliclazide—VEGFA—vagina—urinary bladder cancer	0.00624	0.0446	CbGeAlD
Gliclazide—ABCC8—smooth muscle tissue—urinary bladder cancer	0.0059	0.0421	CbGeAlD
Gliclazide—ABCC8—renal system—urinary bladder cancer	0.00568	0.0405	CbGeAlD
Gliclazide—KCNJ11—female reproductive system—urinary bladder cancer	0.00493	0.0352	CbGeAlD
Gliclazide—VEGFA—lymph node—urinary bladder cancer	0.00404	0.0288	CbGeAlD
Gliclazide—Glipizide—PPARG—urinary bladder cancer	0.00294	1	CrCbGaD
Gliclazide—KCNJ11—lymph node—urinary bladder cancer	0.00289	0.0206	CbGeAlD
Gliclazide—CYP2C19—vagina—urinary bladder cancer	0.00237	0.0169	CbGeAlD
Gliclazide—CYP2C9—female reproductive system—urinary bladder cancer	0.00203	0.0145	CbGeAlD
Gliclazide—ALB—lymph node—urinary bladder cancer	0.0019	0.0136	CbGeAlD
Gliclazide—Pharyngitis—Methotrexate—urinary bladder cancer	0.000312	0.000629	CcSEcCtD
Gliclazide—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000311	0.000625	CcSEcCtD
Gliclazide—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00031	0.000624	CcSEcCtD
Gliclazide—Weight increased—Doxorubicin—urinary bladder cancer	0.00031	0.000624	CcSEcCtD
Gliclazide—Epistaxis—Epirubicin—urinary bladder cancer	0.000309	0.000623	CcSEcCtD
Gliclazide—Pruritus—Gemcitabine—urinary bladder cancer	0.000309	0.000622	CcSEcCtD
Gliclazide—Nausea—Thiotepa—urinary bladder cancer	0.000308	0.000621	CcSEcCtD
Gliclazide—Sinusitis—Epirubicin—urinary bladder cancer	0.000308	0.000619	CcSEcCtD
Gliclazide—Feeling abnormal—Etoposide—urinary bladder cancer	0.000307	0.000619	CcSEcCtD
Gliclazide—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000307	0.000618	CcSEcCtD
Gliclazide—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000306	0.000616	CcSEcCtD
Gliclazide—Pneumonia—Doxorubicin—urinary bladder cancer	0.000305	0.000614	CcSEcCtD
Gliclazide—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000305	0.000614	CcSEcCtD
Gliclazide—Pruritus—Fluorouracil—urinary bladder cancer	0.000304	0.000612	CcSEcCtD
Gliclazide—Drowsiness—Doxorubicin—urinary bladder cancer	0.000303	0.000611	CcSEcCtD
Gliclazide—Visual impairment—Methotrexate—urinary bladder cancer	0.000303	0.00061	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000301	0.000606	CcSEcCtD
Gliclazide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.0003	0.000604	CcSEcCtD
Gliclazide—Bradycardia—Epirubicin—urinary bladder cancer	0.0003	0.000603	CcSEcCtD
Gliclazide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000299	0.000602	CcSEcCtD
Gliclazide—Renal failure—Doxorubicin—urinary bladder cancer	0.000298	0.000601	CcSEcCtD
Gliclazide—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000297	0.000599	CcSEcCtD
Gliclazide—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000297	0.000599	CcSEcCtD
Gliclazide—Urticaria—Etoposide—urinary bladder cancer	0.000296	0.000597	CcSEcCtD
Gliclazide—Jaundice—Doxorubicin—urinary bladder cancer	0.000296	0.000595	CcSEcCtD
Gliclazide—Rhinitis—Epirubicin—urinary bladder cancer	0.000295	0.000594	CcSEcCtD
Gliclazide—Abdominal pain—Etoposide—urinary bladder cancer	0.000295	0.000594	CcSEcCtD
Gliclazide—Body temperature increased—Etoposide—urinary bladder cancer	0.000295	0.000594	CcSEcCtD
Gliclazide—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000295	0.000594	CcSEcCtD
Gliclazide—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000295	0.000594	CcSEcCtD
Gliclazide—Hepatitis—Epirubicin—urinary bladder cancer	0.000294	0.000593	CcSEcCtD
Gliclazide—Eye disorder—Methotrexate—urinary bladder cancer	0.000294	0.000592	CcSEcCtD
Gliclazide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000294	0.000592	CcSEcCtD
Gliclazide—Tinnitus—Methotrexate—urinary bladder cancer	0.000293	0.000591	CcSEcCtD
Gliclazide—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000293	0.00059	CcSEcCtD
Gliclazide—Asthenia—Cisplatin—urinary bladder cancer	0.000292	0.000588	CcSEcCtD
Gliclazide—Pharyngitis—Epirubicin—urinary bladder cancer	0.000292	0.000588	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—urinary bladder cancer	0.000291	0.000586	CcSEcCtD
Gliclazide—Oedema peripheral—Epirubicin—urinary bladder cancer	0.00029	0.000584	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000287	0.000578	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—urinary bladder cancer	0.000286	0.000576	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—urinary bladder cancer	0.000285	0.000573	CcSEcCtD
Gliclazide—Dizziness—Fluorouracil—urinary bladder cancer	0.000284	0.000572	CcSEcCtD
Gliclazide—Visual impairment—Epirubicin—urinary bladder cancer	0.000284	0.000571	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000283	0.00057	CcSEcCtD
Gliclazide—Chills—Methotrexate—urinary bladder cancer	0.000282	0.000568	CcSEcCtD
Gliclazide—Diarrhoea—Cisplatin—urinary bladder cancer	0.000279	0.000561	CcSEcCtD
Gliclazide—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000278	0.00056	CcSEcCtD
Gliclazide—Vomiting—Gemcitabine—urinary bladder cancer	0.000278	0.000559	CcSEcCtD
Gliclazide—Bradycardia—Doxorubicin—urinary bladder cancer	0.000277	0.000558	CcSEcCtD
Gliclazide—Mental disorder—Methotrexate—urinary bladder cancer	0.000276	0.000555	CcSEcCtD
Gliclazide—Rash—Gemcitabine—urinary bladder cancer	0.000275	0.000555	CcSEcCtD
Gliclazide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000275	0.000554	CcSEcCtD
Gliclazide—Eye disorder—Epirubicin—urinary bladder cancer	0.000275	0.000554	CcSEcCtD
Gliclazide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000275	0.000553	CcSEcCtD
Gliclazide—Tinnitus—Epirubicin—urinary bladder cancer	0.000274	0.000553	CcSEcCtD
Gliclazide—Erythema—Methotrexate—urinary bladder cancer	0.000274	0.000551	CcSEcCtD
Gliclazide—Malnutrition—Methotrexate—urinary bladder cancer	0.000274	0.000551	CcSEcCtD
Gliclazide—Headache—Gemcitabine—urinary bladder cancer	0.000274	0.000551	CcSEcCtD
Gliclazide—Flushing—Epirubicin—urinary bladder cancer	0.000273	0.00055	CcSEcCtD
Gliclazide—Vomiting—Fluorouracil—urinary bladder cancer	0.000273	0.00055	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—urinary bladder cancer	0.000273	0.00055	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—urinary bladder cancer	0.000272	0.000548	CcSEcCtD
Gliclazide—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000271	0.000546	CcSEcCtD
Gliclazide—Rash—Fluorouracil—urinary bladder cancer	0.000271	0.000545	CcSEcCtD
Gliclazide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000271	0.000545	CcSEcCtD
Gliclazide—Pharyngitis—Doxorubicin—urinary bladder cancer	0.00027	0.000544	CcSEcCtD
Gliclazide—Headache—Fluorouracil—urinary bladder cancer	0.000269	0.000542	CcSEcCtD
Gliclazide—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000268	0.00054	CcSEcCtD
Gliclazide—Asthenia—Etoposide—urinary bladder cancer	0.000268	0.000539	CcSEcCtD
Gliclazide—Back pain—Methotrexate—urinary bladder cancer	0.000265	0.000533	CcSEcCtD
Gliclazide—Chills—Epirubicin—urinary bladder cancer	0.000264	0.000532	CcSEcCtD
Gliclazide—Pruritus—Etoposide—urinary bladder cancer	0.000264	0.000531	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—urinary bladder cancer	0.000263	0.000529	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—urinary bladder cancer	0.000262	0.000529	CcSEcCtD
Gliclazide—Nausea—Gemcitabine—urinary bladder cancer	0.000259	0.000523	CcSEcCtD
Gliclazide—Vomiting—Cisplatin—urinary bladder cancer	0.000259	0.000521	CcSEcCtD
Gliclazide—Mental disorder—Epirubicin—urinary bladder cancer	0.000258	0.000519	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000258	0.000519	CcSEcCtD
Gliclazide—Rash—Cisplatin—urinary bladder cancer	0.000257	0.000517	CcSEcCtD
Gliclazide—Dermatitis—Cisplatin—urinary bladder cancer	0.000257	0.000517	CcSEcCtD
Gliclazide—Erythema—Epirubicin—urinary bladder cancer	0.000256	0.000516	CcSEcCtD
Gliclazide—Malnutrition—Epirubicin—urinary bladder cancer	0.000256	0.000516	CcSEcCtD
Gliclazide—Diarrhoea—Etoposide—urinary bladder cancer	0.000255	0.000514	CcSEcCtD
Gliclazide—Nausea—Fluorouracil—urinary bladder cancer	0.000255	0.000514	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—urinary bladder cancer	0.000255	0.000513	CcSEcCtD
Gliclazide—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000254	0.000512	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—urinary bladder cancer	0.000254	0.000511	CcSEcCtD
Gliclazide—Anaemia—Methotrexate—urinary bladder cancer	0.000253	0.00051	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—urinary bladder cancer	0.000253	0.000509	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—urinary bladder cancer	0.000252	0.000508	CcSEcCtD
Gliclazide—Tension—Epirubicin—urinary bladder cancer	0.000251	0.000506	CcSEcCtD
Gliclazide—Nervousness—Epirubicin—urinary bladder cancer	0.000249	0.000501	CcSEcCtD
Gliclazide—Back pain—Epirubicin—urinary bladder cancer	0.000248	0.000499	CcSEcCtD
Gliclazide—Malaise—Methotrexate—urinary bladder cancer	0.000247	0.000497	CcSEcCtD
Gliclazide—Dizziness—Etoposide—urinary bladder cancer	0.000247	0.000497	CcSEcCtD
Gliclazide—Leukopenia—Methotrexate—urinary bladder cancer	0.000245	0.000494	CcSEcCtD
Gliclazide—Chills—Doxorubicin—urinary bladder cancer	0.000244	0.000492	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000243	0.00049	CcSEcCtD
Gliclazide—Nausea—Cisplatin—urinary bladder cancer	0.000242	0.000487	CcSEcCtD
Gliclazide—ABCC8—Metabolism—TYMP—urinary bladder cancer	0.000239	0.000938	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	0.000239	0.000938	CbGpPWpGaD
Gliclazide—Cough—Methotrexate—urinary bladder cancer	0.000239	0.000481	CcSEcCtD
Gliclazide—Mental disorder—Doxorubicin—urinary bladder cancer	0.000239	0.00048	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000238	0.000479	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—urinary bladder cancer	0.000237	0.000478	CcSEcCtD
Gliclazide—Vomiting—Etoposide—urinary bladder cancer	0.000237	0.000478	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—urinary bladder cancer	0.000237	0.000477	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—urinary bladder cancer	0.000237	0.000477	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—urinary bladder cancer	0.000237	0.000477	CcSEcCtD
Gliclazide—Agitation—Epirubicin—urinary bladder cancer	0.000235	0.000474	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000235	0.000923	CbGpPWpGaD
Gliclazide—Rash—Etoposide—urinary bladder cancer	0.000235	0.000474	CcSEcCtD
Gliclazide—Dermatitis—Etoposide—urinary bladder cancer	0.000235	0.000473	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000235	0.000921	CbGpPWpGaD
Gliclazide—Headache—Etoposide—urinary bladder cancer	0.000234	0.000471	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—urinary bladder cancer	0.000234	0.00047	CcSEcCtD
Gliclazide—Arthralgia—Methotrexate—urinary bladder cancer	0.000233	0.000469	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—urinary bladder cancer	0.000233	0.000469	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—urinary bladder cancer	0.000233	0.000469	CcSEcCtD
Gliclazide—Tension—Doxorubicin—urinary bladder cancer	0.000233	0.000468	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—TYMP—urinary bladder cancer	0.000232	0.000909	CbGpPWpGaD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000231	0.000466	CcSEcCtD
Gliclazide—Malaise—Epirubicin—urinary bladder cancer	0.000231	0.000465	CcSEcCtD
Gliclazide—Discomfort—Methotrexate—urinary bladder cancer	0.00023	0.000464	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—urinary bladder cancer	0.00023	0.000464	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—urinary bladder cancer	0.000229	0.000462	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—urinary bladder cancer	0.000229	0.000462	CcSEcCtD
Gliclazide—Palpitations—Epirubicin—urinary bladder cancer	0.000226	0.000456	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—IL2—urinary bladder cancer	0.000226	0.000888	CbGpPWpGaD
Gliclazide—Confusional state—Methotrexate—urinary bladder cancer	0.000225	0.000454	CcSEcCtD
Gliclazide—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000225	0.000453	CcSEcCtD
Gliclazide—Cough—Epirubicin—urinary bladder cancer	0.000224	0.00045	CcSEcCtD
Gliclazide—Convulsion—Epirubicin—urinary bladder cancer	0.000222	0.000447	CcSEcCtD
Gliclazide—Infection—Methotrexate—urinary bladder cancer	0.000222	0.000447	CcSEcCtD
Gliclazide—Nausea—Etoposide—urinary bladder cancer	0.000222	0.000446	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—CXCL8—urinary bladder cancer	0.000221	0.000869	CbGpPWpGaD
Gliclazide—Hypertension—Epirubicin—urinary bladder cancer	0.000221	0.000445	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00022	0.000443	CcSEcCtD
Gliclazide—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000219	0.000441	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—urinary bladder cancer	0.000219	0.000441	CcSEcCtD
Gliclazide—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000219	0.000441	CcSEcCtD
Gliclazide—Arthralgia—Epirubicin—urinary bladder cancer	0.000218	0.000439	CcSEcCtD
Gliclazide—Chest pain—Epirubicin—urinary bladder cancer	0.000218	0.000439	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—urinary bladder cancer	0.000218	0.000439	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—HDAC4—urinary bladder cancer	0.000218	0.000855	CbGpPWpGaD
Gliclazide—Agitation—Doxorubicin—urinary bladder cancer	0.000218	0.000439	CcSEcCtD
Gliclazide—Anxiety—Epirubicin—urinary bladder cancer	0.000217	0.000438	CcSEcCtD
Gliclazide—Skin disorder—Methotrexate—urinary bladder cancer	0.000217	0.000437	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000217	0.000436	CcSEcCtD
Gliclazide—ABCC8—Metabolism—NAT2—urinary bladder cancer	0.000216	0.000848	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000216	0.000435	CcSEcCtD
Gliclazide—Discomfort—Epirubicin—urinary bladder cancer	0.000216	0.000434	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	0.000214	0.000841	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—RHOA—urinary bladder cancer	0.000214	0.00084	CbGpPWpGaD
Gliclazide—Malaise—Doxorubicin—urinary bladder cancer	0.000214	0.000431	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—urinary bladder cancer	0.000213	0.00043	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	0.000213	0.000835	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	0.000212	0.000833	CbGpPWpGaD
Gliclazide—Leukopenia—Doxorubicin—urinary bladder cancer	0.000212	0.000427	CcSEcCtD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000211	0.000828	CbGpPWpGaD
Gliclazide—Confusional state—Epirubicin—urinary bladder cancer	0.000211	0.000425	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—EGFR—urinary bladder cancer	0.000211	0.000826	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	0.00021	0.000822	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NAT2—urinary bladder cancer	0.00021	0.000822	CbGpPWpGaD
Gliclazide—Palpitations—Doxorubicin—urinary bladder cancer	0.00021	0.000422	CcSEcCtD
Gliclazide—Hypotension—Methotrexate—urinary bladder cancer	0.000209	0.00042	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000208	0.00042	CcSEcCtD
Gliclazide—Infection—Epirubicin—urinary bladder cancer	0.000208	0.000418	CcSEcCtD
Gliclazide—Cough—Doxorubicin—urinary bladder cancer	0.000207	0.000417	CcSEcCtD
Gliclazide—Convulsion—Doxorubicin—urinary bladder cancer	0.000205	0.000414	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000205	0.000413	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000205	0.000412	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—urinary bladder cancer	0.000205	0.000412	CcSEcCtD
Gliclazide—Tachycardia—Epirubicin—urinary bladder cancer	0.000204	0.000411	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000204	0.00041	CcSEcCtD
Gliclazide—Skin disorder—Epirubicin—urinary bladder cancer	0.000203	0.000409	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	0.000203	0.000795	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000202	0.000407	CcSEcCtD
Gliclazide—Insomnia—Methotrexate—urinary bladder cancer	0.000202	0.000407	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—urinary bladder cancer	0.000202	0.000406	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—urinary bladder cancer	0.000202	0.000406	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—urinary bladder cancer	0.000202	0.000406	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—urinary bladder cancer	0.000201	0.000405	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—PLAU—urinary bladder cancer	0.000201	0.000788	CbGpPWpGaD
Gliclazide—Paraesthesia—Methotrexate—urinary bladder cancer	0.000201	0.000404	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.0002	0.000404	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	0.0002	0.000783	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—CDKN1A—urinary bladder cancer	0.0002	0.000783	CbGpPWpGaD
Gliclazide—Discomfort—Doxorubicin—urinary bladder cancer	0.000199	0.000402	CcSEcCtD
Gliclazide—Dyspnoea—Methotrexate—urinary bladder cancer	0.000199	0.000401	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—urinary bladder cancer	0.000199	0.0004	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—ERBB2—urinary bladder cancer	0.000198	0.000777	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	0.000198	0.000777	CbGpPWpGaD
Gliclazide—Dry mouth—Doxorubicin—urinary bladder cancer	0.000197	0.000398	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—urinary bladder cancer	0.000197	0.000396	CcSEcCtD
Gliclazide—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	0.000197	0.000772	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000196	0.00077	CbGpPWpGaD
Gliclazide—Hypotension—Epirubicin—urinary bladder cancer	0.000195	0.000393	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—urinary bladder cancer	0.000195	0.000393	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000194	0.000761	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000194	0.000761	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CDK4—urinary bladder cancer	0.000193	0.000759	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000193	0.000388	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—urinary bladder cancer	0.000193	0.000388	CcSEcCtD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000193	0.000755	CbGpPWpGaD
Gliclazide—Infection—Doxorubicin—urinary bladder cancer	0.000192	0.000387	CcSEcCtD
Gliclazide—Pain—Methotrexate—urinary bladder cancer	0.000191	0.000385	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000191	0.000384	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—EP300—urinary bladder cancer	0.00019	0.000745	CbGpPWpGaD
Gliclazide—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00019	0.000382	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000189	0.000381	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—urinary bladder cancer	0.000189	0.000381	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—urinary bladder cancer	0.000189	0.00038	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—urinary bladder cancer	0.000188	0.000378	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—urinary bladder cancer	0.000188	0.000378	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000187	0.000377	CcSEcCtD
Gliclazide—ABCC8—Metabolism—RRM2—urinary bladder cancer	0.000187	0.000732	CbGpPWpGaD
Gliclazide—Dyspnoea—Epirubicin—urinary bladder cancer	0.000186	0.000375	CcSEcCtD
Gliclazide—Somnolence—Epirubicin—urinary bladder cancer	0.000186	0.000374	CcSEcCtD
Gliclazide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000184	0.000371	CcSEcCtD
Gliclazide—Dyspepsia—Epirubicin—urinary bladder cancer	0.000184	0.000371	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000183	0.000368	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—GLI1—urinary bladder cancer	0.000183	0.000716	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—RRM2—urinary bladder cancer	0.000181	0.00071	CbGpPWpGaD
Gliclazide—Hypotension—Doxorubicin—urinary bladder cancer	0.000181	0.000364	CcSEcCtD
Gliclazide—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	0.000181	0.000709	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000181	0.000364	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—urinary bladder cancer	0.00018	0.000363	CcSEcCtD
Gliclazide—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000179	0.000703	CbGpPWpGaD
Gliclazide—Constipation—Epirubicin—urinary bladder cancer	0.000179	0.00036	CcSEcCtD
Gliclazide—Pain—Epirubicin—urinary bladder cancer	0.000179	0.00036	CcSEcCtD
Gliclazide—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000178	0.000699	CbGpPWpGaD
Gliclazide—Urticaria—Methotrexate—urinary bladder cancer	0.000178	0.000357	CcSEcCtD
Gliclazide—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000177	0.000694	CbGpPWpGaD
Gliclazide—Body temperature increased—Methotrexate—urinary bladder cancer	0.000177	0.000356	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—urinary bladder cancer	0.000177	0.000356	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000176	0.000355	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	0.000176	0.000691	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—PPARG—urinary bladder cancer	0.000176	0.00069	CbGpPWpGaD
Gliclazide—Insomnia—Doxorubicin—urinary bladder cancer	0.000175	0.000352	CcSEcCtD
Gliclazide—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000174	0.00035	CcSEcCtD
Gliclazide—ABCC8—Metabolism—ENO2—urinary bladder cancer	0.000173	0.000678	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—HPGDS—urinary bladder cancer	0.000173	0.000678	CbGpPWpGaD
Gliclazide—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000173	0.000347	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000172	0.000347	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—urinary bladder cancer	0.000172	0.000346	CcSEcCtD
Gliclazide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000171	0.000344	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00017	0.000343	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—MMP9—urinary bladder cancer	0.00017	0.000667	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—HRAS—urinary bladder cancer	0.000169	0.000663	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CREBBP—urinary bladder cancer	0.000169	0.000662	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTT1—urinary bladder cancer	0.000168	0.000658	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ENO2—urinary bladder cancer	0.000168	0.000657	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—HPGDS—urinary bladder cancer	0.000168	0.000657	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000167	0.000336	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—urinary bladder cancer	0.000167	0.000336	CcSEcCtD
Gliclazide—Urticaria—Epirubicin—urinary bladder cancer	0.000166	0.000335	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—CREBBP—urinary bladder cancer	0.000166	0.00065	CbGpPWpGaD
Gliclazide—Pain—Doxorubicin—urinary bladder cancer	0.000165	0.000333	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—urinary bladder cancer	0.000165	0.000333	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—urinary bladder cancer	0.000165	0.000333	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000165	0.000333	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—TNF—urinary bladder cancer	0.000165	0.000647	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000165	0.000646	CbGpPWpGaD
Gliclazide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000165	0.000332	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—IGF1—urinary bladder cancer	0.000164	0.000642	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTT1—urinary bladder cancer	0.000163	0.000638	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000163	0.000638	CbGpPWpGaD
Gliclazide—Asthenia—Methotrexate—urinary bladder cancer	0.00016	0.000323	CcSEcCtD
Gliclazide—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.00016	0.000628	CbGpPWpGaD
Gliclazide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000159	0.000321	CcSEcCtD
Gliclazide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000158	0.000319	CcSEcCtD
Gliclazide—Pruritus—Methotrexate—urinary bladder cancer	0.000158	0.000318	CcSEcCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.000157	0.000616	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—SRC—urinary bladder cancer	0.000157	0.000615	CbGpPWpGaD
Gliclazide—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000154	0.00031	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—urinary bladder cancer	0.000154	0.00031	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000153	0.000308	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000153	0.000308	CcSEcCtD
Gliclazide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000153	0.000308	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—RHOA—urinary bladder cancer	0.000153	0.000599	CbGpPWpGaD
Gliclazide—Asthenia—Epirubicin—urinary bladder cancer	0.00015	0.000302	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—RHOA—urinary bladder cancer	0.00015	0.000588	CbGpPWpGaD
Gliclazide—Pruritus—Epirubicin—urinary bladder cancer	0.000148	0.000298	CcSEcCtD
Gliclazide—Dizziness—Methotrexate—urinary bladder cancer	0.000148	0.000298	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—TP53—urinary bladder cancer	0.000145	0.00057	CbGpPWpGaD
Gliclazide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000143	0.000288	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000143	0.000287	CcSEcCtD
Gliclazide—Vomiting—Methotrexate—urinary bladder cancer	0.000142	0.000286	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—ERBB2—urinary bladder cancer	0.000141	0.000555	CbGpPWpGaD
Gliclazide—Rash—Methotrexate—urinary bladder cancer	0.000141	0.000284	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—urinary bladder cancer	0.000141	0.000283	CcSEcCtD
Gliclazide—Headache—Methotrexate—urinary bladder cancer	0.00014	0.000282	CcSEcCtD
Gliclazide—ABCC8—Metabolism—NQO1—urinary bladder cancer	0.000139	0.000547	CbGpPWpGaD
Gliclazide—Asthenia—Doxorubicin—urinary bladder cancer	0.000139	0.00028	CcSEcCtD
Gliclazide—Dizziness—Epirubicin—urinary bladder cancer	0.000138	0.000278	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—EGFR—urinary bladder cancer	0.000137	0.000539	CbGpPWpGaD
Gliclazide—Pruritus—Doxorubicin—urinary bladder cancer	0.000137	0.000276	CcSEcCtD
Gliclazide—ABCC8—Neuronal System—HRAS—urinary bladder cancer	0.000136	0.000534	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—urinary bladder cancer	0.000136	0.000533	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NQO1—urinary bladder cancer	0.000135	0.00053	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTZ1—urinary bladder cancer	0.000134	0.000526	CbGpPWpGaD
Gliclazide—Vomiting—Epirubicin—urinary bladder cancer	0.000133	0.000268	CcSEcCtD
Gliclazide—Nausea—Methotrexate—urinary bladder cancer	0.000133	0.000267	CcSEcCtD
Gliclazide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000132	0.000267	CcSEcCtD
Gliclazide—KCNJ11—Neuronal System—HRAS—urinary bladder cancer	0.000132	0.000518	CbGpPWpGaD
Gliclazide—Rash—Epirubicin—urinary bladder cancer	0.000132	0.000266	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—urinary bladder cancer	0.000132	0.000265	CcSEcCtD
Gliclazide—Headache—Epirubicin—urinary bladder cancer	0.000131	0.000264	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	0.000131	0.000514	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—KRAS—urinary bladder cancer	0.00013	0.000509	CbGpPWpGaD
Gliclazide—Dizziness—Doxorubicin—urinary bladder cancer	0.000128	0.000258	CcSEcCtD
Gliclazide—ALB—Metabolism—GSTO2—urinary bladder cancer	0.000127	0.000499	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NAT1—urinary bladder cancer	0.000127	0.000499	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL2—urinary bladder cancer	0.000126	0.000493	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RBX1—urinary bladder cancer	0.000125	0.000491	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000125	0.000491	CbGpPWpGaD
Gliclazide—Nausea—Epirubicin—urinary bladder cancer	0.000124	0.00025	CcSEcCtD
Gliclazide—Vomiting—Doxorubicin—urinary bladder cancer	0.000123	0.000248	CcSEcCtD
Gliclazide—Rash—Doxorubicin—urinary bladder cancer	0.000122	0.000246	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000122	0.000245	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—MMP9—urinary bladder cancer	0.000121	0.000476	CbGpPWpGaD
Gliclazide—Headache—Doxorubicin—urinary bladder cancer	0.000121	0.000244	CcSEcCtD
Gliclazide—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	0.00012	0.000473	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TSC1—urinary bladder cancer	0.000118	0.000462	CbGpPWpGaD
Gliclazide—ALB—Metabolism—UGT2B7—urinary bladder cancer	0.000116	0.000456	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTP1—urinary bladder cancer	0.000116	0.000456	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EP300—urinary bladder cancer	0.000115	0.000451	CbGpPWpGaD
Gliclazide—Nausea—Doxorubicin—urinary bladder cancer	0.000115	0.000231	CcSEcCtD
Gliclazide—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	0.000114	0.000448	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NAT1—urinary bladder cancer	0.000114	0.000448	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—EP300—urinary bladder cancer	0.000113	0.000443	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTP1—urinary bladder cancer	0.000113	0.000442	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000112	0.000441	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JAG1—urinary bladder cancer	0.000112	0.00044	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	0.000112	0.000439	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—SRC—urinary bladder cancer	0.000112	0.000439	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—HRAS—urinary bladder cancer	0.00011	0.000433	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.00011	0.000431	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SRC—urinary bladder cancer	0.00011	0.00043	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000108	0.000424	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—TYMS—urinary bladder cancer	0.000108	0.000424	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NCOR1—urinary bladder cancer	0.000107	0.000419	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTM1—urinary bladder cancer	0.000107	0.000419	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP4B1—urinary bladder cancer	0.000105	0.000411	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—TYMS—urinary bladder cancer	0.000105	0.000411	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	0.000104	0.00041	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.000104	0.000409	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.000104	0.000409	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NCOR1—urinary bladder cancer	0.000104	0.000406	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTM1—urinary bladder cancer	0.000104	0.000406	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	0.000103	0.000403	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000102	0.000402	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GPX1—urinary bladder cancer	0.000102	0.000401	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ERCC2—urinary bladder cancer	0.0001	0.000394	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IFNA2—urinary bladder cancer	9.99e-05	0.000392	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GPX1—urinary bladder cancer	9.92e-05	0.000389	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC19A1—urinary bladder cancer	9.89e-05	0.000388	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EGFR—urinary bladder cancer	9.8e-05	0.000385	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ERCC2—urinary bladder cancer	9.73e-05	0.000382	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PRSS3—urinary bladder cancer	9.64e-05	0.000378	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	9.52e-05	0.000374	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—MTHFR—urinary bladder cancer	9.44e-05	0.00037	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	9.4e-05	0.000369	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TNF—urinary bladder cancer	9.34e-05	0.000366	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KRAS—urinary bladder cancer	9.26e-05	0.000363	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—MTHFR—urinary bladder cancer	9.15e-05	0.000359	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KRAS—urinary bladder cancer	9.08e-05	0.000356	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—S100B—urinary bladder cancer	9.07e-05	0.000356	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	8.88e-05	0.000348	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	8.66e-05	0.00034	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	8.61e-05	0.000338	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	8.58e-05	0.000336	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NCOR1—urinary bladder cancer	8.16e-05	0.00032	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	8.1e-05	0.000318	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—urinary bladder cancer	8.07e-05	0.000317	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	7.89e-05	0.00031	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—urinary bladder cancer	7.87e-05	0.000309	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.73e-05	0.000303	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—urinary bladder cancer	7.72e-05	0.000303	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TYMP—urinary bladder cancer	7.71e-05	0.000302	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPARG—urinary bladder cancer	7.65e-05	0.0003	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	7.51e-05	0.000295	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPARG—urinary bladder cancer	7.42e-05	0.000291	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.4e-05	0.00029	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CREBBP—urinary bladder cancer	7.35e-05	0.000288	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TERT—urinary bladder cancer	7.19e-05	0.000282	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CREBBP—urinary bladder cancer	7.13e-05	0.00028	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PLAU—urinary bladder cancer	7.09e-05	0.000278	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NAT2—urinary bladder cancer	6.97e-05	0.000273	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.94e-05	0.000272	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TYMP—urinary bladder cancer	6.92e-05	0.000271	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.65e-05	0.000261	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGFR3—urinary bladder cancer	6.6e-05	0.000259	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ESR1—urinary bladder cancer	6.41e-05	0.000251	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.33e-05	0.000248	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TYMP—urinary bladder cancer	6.31e-05	0.000248	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NAT2—urinary bladder cancer	6.26e-05	0.000245	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.06e-05	0.000238	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—urinary bladder cancer	6.02e-05	0.000236	CbGpPWpGaD
Gliclazide—ALB—Metabolism—RRM2—urinary bladder cancer	6.02e-05	0.000236	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CREBBP—urinary bladder cancer	5.85e-05	0.000229	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—urinary bladder cancer	5.84e-05	0.000229	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IGF1—urinary bladder cancer	5.77e-05	0.000226	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NAT2—urinary bladder cancer	5.71e-05	0.000224	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CREBBP—urinary bladder cancer	5.62e-05	0.00022	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HPGDS—urinary bladder cancer	5.57e-05	0.000219	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ENO2—urinary bladder cancer	5.57e-05	0.000219	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF1—urinary bladder cancer	5.55e-05	0.000218	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.54e-05	0.000217	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTT1—urinary bladder cancer	5.4e-05	0.000212	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—RRM2—urinary bladder cancer	5.4e-05	0.000212	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.32e-05	0.000209	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—RHOA—urinary bladder cancer	5.29e-05	0.000207	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTEN—urinary bladder cancer	5.25e-05	0.000206	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTEN—urinary bladder cancer	5.09e-05	0.0002	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RHOA—urinary bladder cancer	5.08e-05	0.000199	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.06e-05	0.000199	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—EP300—urinary bladder cancer	5.01e-05	0.000196	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ENO2—urinary bladder cancer	5e-05	0.000196	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	5e-05	0.000196	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.97e-05	0.000195	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—RRM2—urinary bladder cancer	4.93e-05	0.000193	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—EP300—urinary bladder cancer	4.85e-05	0.00019	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	4.85e-05	0.00019	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.78e-05	0.000187	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ERBB2—urinary bladder cancer	4.7e-05	0.000185	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	4.56e-05	0.000179	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ENO2—urinary bladder cancer	4.56e-05	0.000179	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.53e-05	0.000178	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NQO1—urinary bladder cancer	4.49e-05	0.000176	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL8—urinary bladder cancer	4.46e-05	0.000175	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—urinary bladder cancer	4.44e-05	0.000174	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	4.42e-05	0.000174	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.36e-05	0.000171	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.36e-05	0.000171	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—urinary bladder cancer	4.26e-05	0.000167	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—urinary bladder cancer	4.16e-05	0.000163	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—urinary bladder cancer	4.03e-05	0.000158	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NQO1—urinary bladder cancer	4.03e-05	0.000158	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1A—urinary bladder cancer	4.02e-05	0.000158	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTEN—urinary bladder cancer	4.01e-05	0.000157	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—EP300—urinary bladder cancer	3.98e-05	0.000156	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.91e-05	0.000153	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SRC—urinary bladder cancer	3.87e-05	0.000152	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EP300—urinary bladder cancer	3.82e-05	0.00015	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.8e-05	0.000149	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTP1—urinary bladder cancer	3.75e-05	0.000147	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SRC—urinary bladder cancer	3.72e-05	0.000146	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3.68e-05	0.000144	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.62e-05	0.000142	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.57e-05	0.00014	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TYMS—urinary bladder cancer	3.48e-05	0.000137	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NCOR1—urinary bladder cancer	3.44e-05	0.000135	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTM1—urinary bladder cancer	3.44e-05	0.000135	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.41e-05	0.000134	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	3.36e-05	0.000132	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—urinary bladder cancer	3.33e-05	0.000131	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GPX1—urinary bladder cancer	3.3e-05	0.000129	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—urinary bladder cancer	3.26e-05	0.000128	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.25e-05	0.000128	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ERCC2—urinary bladder cancer	3.24e-05	0.000127	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—urinary bladder cancer	3.21e-05	0.000126	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TYMS—urinary bladder cancer	3.13e-05	0.000123	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.11e-05	0.000122	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	3.09e-05	0.000121	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	3.09e-05	0.000121	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—urinary bladder cancer	3.08e-05	0.000121	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.07e-05	0.00012	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MTHFR—urinary bladder cancer	3.04e-05	0.000119	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.97e-05	0.000116	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.96e-05	0.000116	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.91e-05	0.000114	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.85e-05	0.000112	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—urinary bladder cancer	2.85e-05	0.000112	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.82e-05	0.000111	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.82e-05	0.000111	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—urinary bladder cancer	2.74e-05	0.000107	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.73e-05	0.000107	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—urinary bladder cancer	2.72e-05	0.000107	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.7e-05	0.000106	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.65e-05	0.000104	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—urinary bladder cancer	2.62e-05	0.000103	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.49e-05	9.77e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARG—urinary bladder cancer	2.47e-05	9.68e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CREBBP—urinary bladder cancer	2.37e-05	9.3e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARG—urinary bladder cancer	2.21e-05	8.69e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	2.13e-05	8.35e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.02e-05	7.92e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—urinary bladder cancer	1.94e-05	7.61e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.94e-05	7.61e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.74e-05	6.84e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTEN—urinary bladder cancer	1.69e-05	6.64e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—EP300—urinary bladder cancer	1.61e-05	6.33e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.59e-05	6.23e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.52e-05	5.96e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.45e-05	5.68e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.39e-05	5.44e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.32e-05	5.18e-05	CbGpPWpGaD
